Preclinical Evaluation of a New Series of Albumin-Binding <sup>177</sup>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2023-08-01
|
| Seri Bilgileri: | Molecules |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1420-3049/28/16/6158 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|